Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Proteolysis of plasminogen activator inhibitor-1 by Yersinia pestis remodulates the host environment to promote virulence.

Eddy JL, Schroeder JA, Zimbler DL, Caulfield AJ, Lathem WW.

J Thromb Haemost. 2016 Sep;14(9):1833-43. doi: 10.1111/jth.13408. Epub 2016 Aug 19.

2.

Inactivation of Peroxiredoxin 6 by the Pla Protease of Yersinia pestis.

Zimbler DL, Eddy JL, Schroeder JA, Lathem WW.

Infect Immun. 2015 Nov 9;84(1):365-74. doi: 10.1128/IAI.01168-15. Print 2016 Jan.

3.

Impact of the Pla protease substrate α2-antiplasmin on the progression of primary pneumonic plague.

Eddy JL, Schroeder JA, Zimbler DL, Bellows LE, Lathem WW.

Infect Immun. 2015 Dec;83(12):4837-47. doi: 10.1128/IAI.01086-15. Epub 2015 Oct 5.

4.

Early emergence of Yersinia pestis as a severe respiratory pathogen.

Zimbler DL, Schroeder JA, Eddy JL, Lathem WW.

Nat Commun. 2015 Jun 30;6:7487. doi: 10.1038/ncomms8487.

5.

Production of outer membrane vesicles by the plague pathogen Yersinia pestis.

Eddy JL, Gielda LM, Caulfield AJ, Rangel SM, Lathem WW.

PLoS One. 2014 Sep 8;9(9):e107002. doi: 10.1371/journal.pone.0107002. eCollection 2014.

6.

Glucocorticoids regulate natural killer cell function epigenetically.

Eddy JL, Krukowski K, Janusek L, Mathews HL.

Cell Immunol. 2014 Jul;290(1):120-30. doi: 10.1016/j.cellimm.2014.05.013. Epub 2014 Jun 18.

7.
8.

Glucocorticoid receptor mediated suppression of natural killer cell activity: identification of associated deacetylase and corepressor molecules.

Bush KA, Krukowski K, Eddy JL, Janusek LW, Mathews HL.

Cell Immunol. 2012 Jan-Feb;275(1-2):80-9. doi: 10.1016/j.cellimm.2012.02.014. Epub 2012 Mar 21.

9.

Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups.

Sausville EA, Eddy JL, Makuch RW, Fischmann AB, Schechter GP, Matthews M, Glatstein E, Ihde DC, Kaye F, Veach SR, et al.

Ann Intern Med. 1988 Sep 1;109(5):372-82.

PMID:
3408055
10.

A trial of combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate.

Seifter EJ, Bunn PA, Cohen MH, Makuch RW, Dunnick NR, Javadpour N, Bensimon H, Eddy JL, Minna JD, Ihde DC.

J Clin Oncol. 1986 Sep;4(9):1365-73.

PMID:
2943877
11.

Combined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up.

Winkler CF, Sausville EA, Ihde DC, Fischmann AB, Schechter GP, Kumar PP, Nibhanupdi JR, Minna JD, Makuch RW, Eddy JL, et al.

J Clin Oncol. 1986 Jul;4(7):1094-100.

PMID:
3088220
12.

Computed tomography of the abdomen and pelvis: documentation of tumor response and progression in disseminated prostate cancer.

Winkler CF, Dunnick NR, Eddy JL, Newman RD, Ihde DC.

Med Pediatr Oncol. 1986;14(1):20-5.

PMID:
3951395
13.

Chemotherapy administration precaution.

Eddy JL, Li J.

Oncol Nurs Forum. 1986 Jan-Feb;13(1):9. No abstract available.

PMID:
3632865
14.
15.

Phase I and pharmacokinetic study of tiazofurin (TCAR, NSC 286193) administered by continuous infusion.

Batist G, Klecker RW Jr, Jayaram HN, Jenkins JF, Grygiel J, Ihde DC, Eddy JL, Fine RL, Kerr IG, Collins JM.

Invest New Drugs. 1985;3(4):349-55.

PMID:
4086242
16.

Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.

Morstyn G, Schechter GP, Ihde DC, Carney DN, Eddy JL, Cohen MH, Minna JD, Bunn PA Jr.

Cancer Treat Rep. 1984 Dec;68(12):1439-46.

PMID:
6391662
17.

Cutaneous T-cell lymphoma.

Eddy JL, Selgas-Cordes R, Curran M.

Am J Nurs. 1984 Feb;84(2):202-6. No abstract available.

PMID:
6559537
18.

Combination chemotherapy of hepatocellular carcinoma with doxorubicin and streptozotocin.

Morstyn G, Ihde DC, Eddy JL, Bunn PA, Cohen MH, Minna JD.

Am J Clin Oncol. 1983 Oct;6(5):547-51.

PMID:
6310986
19.

Comparative value of bone scintigraphy and radiography in monitoring tumor response in systemically treated prostatic carcinoma.

Levenson RM, Sauerbrunn BJ, Bates HR, Newman RD, Eddy JL, Ihde DC.

Radiology. 1983 Feb;146(2):513-8.

PMID:
6294738
20.

Serum acid phosphatase in the assessment of response to systemic therapy in metastatic prostate cancer: comparison of radioimmune and enzymatic assays.

Ihde DC, Belville WD, Mahan DE, Gemski MJ, Eddy JL.

Mil Med. 1982 Nov;147(11):949-52. No abstract available.

PMID:
6817183
21.

Evaluation of weekly escalating doses of dichloromethotrexate in patients with hepatocellular carcinoma and other solid tumors.

Tester WJ, Donehower RC, Eddy JL, Myers CE, Ihde DC.

Cancer Chemother Pharmacol. 1982;8(3):305-10.

PMID:
6290094
22.

Septicemic complications of the cutaneous T-cell lymphomas.

Posner LE, Fossieck BE Jr, Eddy JL, Bunn PA Jr.

Am J Med. 1981 Aug;71(2):210-6.

PMID:
6973273
23.
24.

Combined modality therapy with electron-beam irradiation and systemic chemotherapy for cutaneous T-cell lymphomas.

Bunn PA Jr, Fischmann AB, Schechter GP, Kumar PP, Ihde DC, Cohen MH, Fossieck BE, Gazdar AF, Matthews MJ, Eddy JL, Minna JD.

Cancer Treat Rep. 1979 Apr;63(4):713-7. No abstract available.

PMID:
109208
25.

5-fluorouracil, methyl-CCNU, adriamycin, and mitomycin C in the treatment of advanced gastric cancer.

Bunn PA Jr, Nugent JL, Ihde DC, Cohen MH, Eddy JL, Minna JD.

Cancer Treat Rep. 1978 Sep;62(9):1287-93.

PMID:
356983

Supplemental Content

Support Center